Our pipeline has been designed with a range of oncology products. The anti-PD-1 and anti-PD-L1 antibody candidates, underpinning our immunotherapy, are the backbone of our pipeline. Our Company believes the broad spectrum of indications covered by anti-PD1 antibody drugs would prompt us to rapidly expand our commercialization capabilities. In June 2021, our Company filed an NDA with the NMPA for our anti-PD-1 antibody candidate HX008 (pucotenlimab) in melanoma. In October 2021, our Company filed an NDA with the NMPA for HX008 in MSI-H/dMMR solid tumors. The experience and recognition to be gained from the commercialization of HX008 is expected to help our Company swiftly penetrate various indications of oncology therapeutics as well as different levels of medical institutions, establish a dedicated commercialization team of a considerable scale and strengthen our commercialization capabilities.The Company obtained IND clearance for HX008 in the U.S. in January 2022.

Our Company is also devoted to the development of ADC and oncolytic virus drug products. Our Company houses the leading ADC drug candidate pipeline in China in terms of the number of clinical-stage ADC drug candidates, according to Frost & Sullivan. Our ADC drug candidates are the core of our targeted therapies. Our Company has developed ADC drug candidates, including MRG003, MRG002 and MRG001 in-house since our acquisition of Miracogen Shanghai, developed in-house our ADC drug candidate MRG004A and owns their global rights. MRG003 is the advanced EGFR-targeted ADC in clinical-stage development in China. MRG002 is an innovative HER2-targeted ADC. MRG001 is a clinically advanced CD20-targeted ADC. Our Company received IND approval of MRG004A, a novel TF-targeted site-specifically conjugated ADC, from the NMPA in August 2021. Our Company is also co-developing CMG901, the first CLDN18.2-targeted ADC to have received the IND approval globally, according to Frost & Sullivan, through a joint venture, KYM.The Company also achieved first patient in for MRG002 for HER2 over-expressing BC in March 2022. Furthermore, the Company obtained an IND approval from the NMPA for the combination therapy of MRG003 and HX008. In April 2022, the drug candidate CMG901 (co-developed by us and Keymed) has been granted the Fast Track Designation for the treatment of relapsed/ refractory GC/ GEJ adenocarcinoma and received the Orphan-drug Designation from the FDA.

Our oncolytic virus drug candidates include CG0070, for which our Company owns the development and commercialization rights in Mainland China, Hong Kong and Macau, and OH2 which we co-developed with a business partner. Our Company believes that our comprehensive ADC and oncolytic virus pipeline creates synergies and maximizes our competitive strength in commercialization.The Company also plan to submit an IND for the combination therapy of CG0070 and HX008.